Biogen to seek expanded use of Tysabri for Crohn's
239484
Biogen Idec Inc. of Cambridge will ask a US advisory committee on July 31 to recommend expanding use of the multiple sclerosis drug, Tysabri, for patients with moderate to severe Crohn's disease. A Food and Drug Administration panel will discuss the risks and benefits of the treatment at a meeting in Gaithersburg, Md., according to a notice posted ...
225807
A promising new asthma vaccine that uses genetically engineered bacteria has been shown in animal studies to stop the disease in its tracks and actually reverse asthmatic lung damage, according to results of a California study reported Wednesday by the
10415
A bacterium that causes an intestinal disorder in cattle and sheep has been blamed for triggering the debilitating bowel condition Crohn&#39;s disease in humans.
192250
Genmab A/S (CSE: GEN) announced today that HuMax-CD4 for the treatment of Mycosis Fungoides (MF), which constitutes 75% of all Cutaneous T-cell Lymphomas (CTCL), has been designated an orphan drug by the US Food and Drug Administration (FDA).
700955
If the plans of the Turku-based company Biotie Therapies and the Californian Somaxon Pharmaceuticals work out, Americans could soon have access to a new medicine that is claimed to work against different types ...
68493
Scientists say they have new evidence to support the belief that Crohn&#39;s disease, an irritable bowel condition that affects a half-million Americans, has a bacterial origin.
463623
James C. Mullen,Biogen Idec Inc.Chief executive For Biogen Idec Inc., the return of the multiple sclerosis drug Tysabri to the market and continued sales growth for its cash cow, Avonex, were the highlights of 2006. Chief executive James C. Mullen recently spoke with Globe reporter Jeffrey Krasner about the company's progress and the challenges posed by the 2006 election.
293341
Biogen Idec Inc.&#39;s Tysabri drug for multiple sclerosis may reach patients as soon as next week, and doctors said they plan to prescribe it first to patients who are no longer being helped by older medicines.
127322
Swiss drug maker Novartis Pharma AG said Monday that the Food and Drug Administration approved another use for the company&#39;s Zelnorm irritable bowel drug, clearing Novartis to market the medicine as a treatment for chronic constipation in male and female
626896
Mixing cells and eggs to be allowed in search for new medical treatments.
97416
THE REGION Cambridge Drug maker Biogen Idec Inc. said it would start buying $3 billion worth of its own shares, potentially cutting the number of outstanding shares by one-sixth. Chief executive James Mullen said strong cash flows from sales of Avonex, for multiple sclerosis, and Rituxan, for non-Hodgkin's lymphoma, allowed the company to return money to shareholders in a tender ...
82032
To turn its new multiple sclerosis treatment Antegren into a blockbuster drug with more than $1 billion in annual sales, Biogen Idec and its partner, Elan Pharmaceuticals, might not have to persuade doctors that it is superior to existing interferon treatments. Partial data released by the companies appear to confirm the treatment's outstanding clinical performance.
289071
Today was a day of good news for multiple sclerosis patients: FDA granted approval to a new anti-multiple sclerosis drug Antegren developed by Biogen Idec Inc.
295860
ALBANY, NY A small, preliminary study has found that an experimental drug can offer relief to people suffering from the bowel disorder Crohn&#39;s disease.
145081
For a small biopharmaceutical firm that has yet to get a drug on the market, Medarex Inc. has been keeping some impressive company. Top pharmaceutical and biotech firms, from Johnson &amp; Johnson to Amgen Inc., have been signing deals with Medarex to use its genetically engineered mice as they seek to develop new drugs. The doctored mice have the rare ability to produce human antibodies, which can help fight disease just as natural antibodies do.
482241
The drugmaker bumps into the FDA as it pushes to do more testing of Entereg.
297310
U.S. regulators have approved wider use of Genentech Inc. and Biogen Idec Inc.'s drug Rituxan for patients with a type of lymphoma, the companies announced on Friday.